EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Crohns disease with recombinant human interferon-gamma A randomised, double blind, placebo controlled phase I/II study



Treatment of Crohns disease with recombinant human interferon-gamma A randomised, double blind, placebo controlled phase I/II study



JPGN 31(Supplement 2): S228




(PDF emailed within 1 workday: $29.90)

Accession: 035980388

Download citation: RISBibTeXText



Related references

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. Annals of the Rheumatic Diseases 51(9): 1039-1043, 1992

Results of multicenter placebo controlled double blind randomized phase iii clinical study of treatment of rheumatoid arthritis with recombinant interferon gamma. Rheumatology International 8(2): 87-93, 1988

Recombinant human gamma interferon in the treatment of rheumatoid arthritis a double blind placebo controlled crossover study. Clinical Research 36(3): 534A, 1988

Recombinant human gamma interferon in the treatment of rheumatoid arthritis double blind placebo controlled crossover study. Clinical Research 37(2): 510A, 1989

Recombinant human gamma interferon gifn in the treatment of rheumatoid arthritis ra double blind placebo controlled crossover study. Arthritis & Rheumatism 32(4 SUPPL): S131, 1989

A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to alpha4 integrin in moderate to severely active Crohns disease. Gastroenterology 120(5 Supplement 1): A 127-A 128, April, 2001

A randomised, double-blind, placebo-controlled, dose-comparative study of recombinant human interferon-beta administered by the intralesional route in the treatment of condyloma acuminatum. Journal of Interferon Research 12(SUPPL 1): S94, 1992

Randomised double-blind placebo-controlled trial of recombinant humanised antibody to alpha-4 integrin in active Crohns disease. Gut 44(SUPPL 1): A42, April, 1999

Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway. Multiple Sclerosis 1(6): 372-375, 1996

Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet. Diabetes & Endocrinology 1(4): 275-283, 2014

A phase II randomized, double-blind, placebo-controlled, multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin. Hepatology 34(4 Pt 2): 350A, October, 2001

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases 64(1): 64-69, 2004

Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo. Journal of Rheumatology 15(4): 570-574, 1988

Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Annals of the Rheumatic Diseases 69(9): 1655-1659, 2010